Home Institutions University of Michigan clinical trials Institution Directory
Clinical trials at University of Michigan Sites in Ann Arbor, MI
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:47 PM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1234
Current sort
Recently updated
Campus scope
University of Michigan, Ann Arbor, MI
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 13–24 of 1,234 matching trials with a site at University of Michigan, Ann Arbor, MI.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions Systemic Sclerosis (SSc)
Interventions Efgartigimod PH20 SC, Placebo PH20 SC Combination Product · Other
Lead sponsor argenx Industry
Eligibility 18 Years and older
Enrollment 87 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2027
U.S. locations 9
States / cities Phoenix, Arizona • Los Angeles, California • Plantation, Florida + 6 more
Conditions Patient-Reported Outcome Measures (PROMs), Pragmatic Trial, Adolescent Congenital Heart Disease, Resiliency-building Intervention, Resilience, Psychological, Telemedicine-Based Education
Interventions Telemedicine-based resiliency-building intervention Behavioral
Lead sponsor Carelon Research Other
Eligibility 12 Years to 17 Years
Enrollment 390 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 14
States / cities Stanford, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Conditions Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
Interventions Atezolizumab, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, Magnetic Resonance Imaging, Patient Observation Biological · Procedure · Drug + 1 more
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility 18 Years and older
Enrollment 189 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2028
U.S. locations 264
States / cities Anchorage, Alaska • Phoenix, Arizona • Anaheim, California + 198 more
Conditions Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
Interventions empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo Biological · Other
Lead sponsor argenx Industry
Eligibility 18 Years and older
Enrollment 218 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2030
U.S. locations 16
States / cities Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 12 more
Conditions Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions AP01, Placebo Drug · Other
Lead sponsor Avalyn Pharma Inc. Industry
Eligibility 18 Years and older
Enrollment 398 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2027
U.S. locations 61
States / cities Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
Conditions GVHD
Interventions Vorinostat Drug
Lead sponsor Sung Won Choi Other
Eligibility 1 Year to 26 Years
Enrollment 55 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2028
U.S. locations 1
States / cities Ann Arbor, Michigan
Conditions COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Interventions Biospecimen Collection, Data Collection, Quality-of-Life Assessment, Questionnaire Administration Procedure · Other
Lead sponsor National Cancer Institute (NCI) NIH
Eligibility Not listed
Enrollment 1,877 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2020 – 2027
U.S. locations 928
States / cities Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 589 more
Conditions Heart Failure
Interventions WiSE System Device
Lead sponsor EBR Systems, Inc. Industry
Eligibility 18 Years and older
Enrollment 300 participants
Healthy volunteers Accepts healthy volunteers
Timeline 2018 – 2027
U.S. locations 43
States / cities Huntsville, Alabama • La Jolla, California • Fort Lauderdale, Florida + 37 more
Conditions Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions Renal Denervation (Symplicity Spyral™) Device
Lead sponsor Medtronic Vascular Industry
Eligibility 18 Years and older
Enrollment 1,899 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2021 – 2029
U.S. locations 76
States / cities Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more
Conditions Primary Immune Deficiency
Interventions Not listed
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID) NIH
Eligibility 1 Month to 100 Years
Enrollment 5,000 participants
Healthy volunteers Healthy volunteers not accepted
Timeline Started 2007
U.S. locations 2
States / cities Bethesda, Maryland • Ann Arbor, Michigan
Conditions Leadless Pacemaker, Bradycardia, AV Block, Cardiac Rhythm Disorder
Interventions LivIQ Leadless Pacemaker System Device
Lead sponsor Biotronik, Inc. Industry
Eligibility 18 Years and older
Enrollment 325 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2028
U.S. locations 24
States / cities Burlingame, California • La Jolla, California • Laguna Hills, California + 20 more
Conditions Hypertrophic Cardiomyopathy (HCM)
Interventions None - observational study Other
Lead sponsor Christopher Kramer Other
Eligibility 18 Years to 65 Years
Enrollment 314 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2028
U.S. locations 6
States / cities Boston, Massachusetts • Medford, Massachusetts • Ann Arbor, Michigan + 3 more About this University of Michigan institution page
What this page lists ClinicalTrials.gov records that list University of Michigan in Ann Arbor, MI as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , browse by condition , or browse by U.S. city .